Literature DB >> 19358266

Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade.

Thomas Dünnebier1, Justo Lorenzo Bermejo, Susanne Haas, Hans-Peter Fischer, Christiane B Pierl, Christina Justenhoven, Hiltrud Brauch, Christian Baisch, Michael Gilbert, Volker Harth, Anne Spickenheuer, Sylvia Rabstein, Beate Pesch, Thomas Brüning, Yon-Dschun Ko, Ute Hamann.   

Abstract

UBC9 encodes a protein that conjugates small ubiquitin-related modifier (SUMO) to target proteins resulting in a change of their localization, activity or stability. Genetic variability may affect expression and activity of UBC9 and may have an impact on breast tumor progression. We investigated associations between UBC9 genotypes and histopathological parameters in 1,021 breast cancer cases of the GENICA collection using a single nucleotide polymorphism (SNP) tagging approach. Genotyping analyses were performed by TaqMan(R) allelic discrimination. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by ordinal logistic regression. Multiple imputation based on HapMap data was applied to boost the power of the study. The study revealed significant associations of three UBC9 SNPs with histological grade (rs7187167, p(trend) = 0.001; rs11248866, p(trend) = 0.009; rs8052688, p(trend) = 0.008). Model selection identified a recessive penetrance model for rs7187167 as the best representation of tumor grade (global p = 0.001). This model did not improve by inclusion of additional SNPs in linkage disequilibrium. Imputation of SNPs in a 300 kb region around the genotyped SNPs supported rs7187167 as a major contributor to tumor grade. Compared with common allele carriers, rare homozygotes presented less frequently with high grade tumors (G3 vs. G1: OR 0.26, 95% CI 0.11-0.62; G3 vs. G2: OR 0.45, 95% CI 0.23-0.86). In addition to tumor size, nodal status and estrogen receptor status, multivariate analyses confirmed an independent role of rs7187167 as predictor of tumor grade (p = 0.0003). The present results underline the value of genetic variation in UBC9 for breast cancer prognosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19358266     DOI: 10.1002/ijc.24286

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  Downregulation of SENP1 inhibits cell proliferation, migration and promotes apoptosis in human glioma cells.

Authors:  Qiu-Sheng Zhang; Meng Zhang; Xian-Jian Huang; Xiao-Jia Liu; Wei-Ping Li
Journal:  Oncol Lett       Date:  2016-05-12       Impact factor: 2.967

2.  Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins.

Authors:  Yunlong Qin; Jingyao Xu; Kartik Aysola; Nurjahan Begum; Vaishali Reddy; Yuli Chai; William E Grizzle; Edward E Partridge; E Shyam P Reddy; Veena N Rao
Journal:  J Cell Physiol       Date:  2011-12       Impact factor: 6.384

Review 3.  SUMO and the robustness of cancer.

Authors:  Jacob-Sebastian Seeler; Anne Dejean
Journal:  Nat Rev Cancer       Date:  2017-01-30       Impact factor: 60.716

Review 4.  More modifiers move on DNA damage.

Authors:  Joanna R Morris
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

5.  SUMO modification of menin.

Authors:  Zi-Jie Feng; Buddha Gurung; Guang-Hui Jin; Xiao-Lu Yang; Xian-Xin Hua
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

6.  BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9.

Authors:  Yunlong Qin; Jingyao Xu; Kartik Aysola; Gabriela Oprea; Avinash Reddy; Roland Matthews; Joel Okoli; Alan Cantor; William E Grizzle; Edward E Partridge; E Shyam P Reddy; Charles Landen; Veena N Rao
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

7.  Gene expression patterns in the histopathological classification of epithelial ovarian cancer.

Authors:  Honglan Zhu; Jing Jie Yu
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

8.  Systematic Analysis of the Genetic Variability That Impacts SUMO Conjugation and Their Involvement in Human Diseases.

Authors:  Hao-Dong Xu; Shao-Ping Shi; Xiang Chen; Jian-Ding Qiu
Journal:  Sci Rep       Date:  2015-07-08       Impact factor: 4.379

9.  Estrogen receptor alpha and nuclear factor Y coordinately regulate the transcription of the SUMO-conjugating UBC9 gene in MCF-7 breast cancer cells.

Authors:  Shibo Ying; Thomas Dünnebier; Jing Si; Ute Hamann
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

10.  Sentrin/SUMO specific proteases as novel tissue-selective modulators of vitamin D receptor-mediated signaling.

Authors:  Wai-Ping Lee; Sarita Jena; Declan Doherty; Jaganathan Ventakesh; Joachim Schimdt; Julie Furmick; Tim Widener; Jana Lemau; Peter W Jurutka; Paul D Thompson
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.